Microcalcifications Detected Equally with Synthetic Mammography Plus DBT or FFDM
The two screening methods have similar sensitivity and specificity in finding microcalcifications.
Synthetic mammography (SM) plus digital breast tomosynthesis (DBT) find microcalcifications at a similar rate as full-field digital mammography (FFDM) alone, according to a study published in the journal Radiology.
Researchers from Taiwan and the United States performed a retrospective study to compare the performance of SM plus DBT with FFDM in the detection of microcalcifications on screening mammograms.
Related article:Â Breast Density Estimations in Standard-dose, Synthetic Mammograms
The researchers reviewed 72 consecutive screening mammograms recalled for microcalcifications and 20 controls, evaluated with both FFDM and DBT:
- 54 mammograms with benign microcalcifications
- 18 mammograms with malignant microcalcifications
- 20 screening mammograms without microcalcifications
FFDM alone was compared to synthetic mammography plus DBT. Four readers independently reviewed each data set and microcalcification recalls were tabulated.
The results showed that the reader agreement was kappa value of 0.66 for FFDM and 0.63 for SM plus DBT. Mixed-effects model concluded no differences between modalities.
Â
The researchers concluded that relative to FFDM, SM plus DMT had similar sensitivity and specificity for the detection of microcalcifications previously identified for recall at screening mammography.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
